Verteporfin therapy for CNV secondary to OHS.
Saperstein
David A
DA
Rosenfeld
Philip J
PJ
Bressler
Neil M
NM
Rosa
Robert H
RH
Sternberg
Paul
P
Aaberg
Thomas M
TM
Aaberg
Thomas M
TM
Weisberger
Annemarie
A
D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D015821:Eye Infections, Fungal / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006660:Histoplasmosis / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D019233:Retreatment; D013577:Syndrome; D000077362:Verteporfin; D014792:Visual Acuity
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin